Audiologists’ perceived value of ototoxicity management and barriers to implementation for at-risk cancer patients in VA: the OtoMIC survey
Tóm tắt
Platinum-based chemotherapies used to treat many types of cancers are ototoxic. Ototoxicity management (OtoM) to mitigate the ototoxic outcomes of cancer survivors is recommended practice yet it is not a standard part of oncologic care. Although more than 10,000 patients each year are treated with platinum-based chemotherapies at the US Veterans Health Administration (VA), the current state of OtoM in VA is not well-defined. This study reports on a national survey of VA audiologists’ perceptions regarding OtoM in cancer patients. A 26-item online survey was administered to VA audiologists and service chiefs across the VA’s 18 regional systems of care. Descriptive statistics and deductive thematic analysis were used to analyze the data. The 61 respondents included at least one from each VA region. All reported they felt some form of OtoM was necessary for at-risk cancer patients. A pre-treatment baseline, the ability to detect ototoxicity early, and management of ototoxic effects both during and after treatment were considered high value objectives of OtoM by respondents. Roughly half reported routinely providing these services for patients receiving cisplatin and carboplatin. Respondents disagreed regarding appropriate hearing testing schedules and how to co-manage OtoM responsibilities with oncology. They identified barriers to care that conformed to three themes: care and referral coordination with oncology, audiology workload, and lack of protocols. Although VA audiologists value providing OtoM for cancer patients, only about half perform OtoM for highly ototoxic treatment regimens. The OtoMIC survey provides clinician perspectives to benchmark and address OtoM care gaps. Collaboration between oncology and audiology is needed to improve current OtoM processes, so that cancer survivors can have more control over their long term hearing health.
Tài liệu tham khảo
Travis LB, Fossa SD, Sesso HD, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014;106(5):dju044. https://doi.org/10.1093/jnci/dju044.
Knight KRG, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23(34):8588–96. https://doi.org/10.1200/JCO.2004.00.5355.
Rybak LP, Ramkumar V. Ototoxicity. Kidney Int. 2007;72(8):931–5. https://doi.org/10.1038/sj.ki.5002434.
Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales—a report from the Children’s Oncology Group. JCO. 2014;32(6):527–34. https://doi.org/10.1200/JCO.2013.51.2038.
Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5(Suppl 1):3–29. https://doi.org/10.2147/CLEP.S47150.
Bielefeld EC, Tanaka C, di Chen G, et al. An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect. Anti-Cancer Drugs. 2013;24(1):43–51. https://doi.org/10.1097/CAD.0b013e32835739fd.
Prayuenyong P, Taylor JA, Pearson SE, et al. Vestibulotoxicity associated with platinum-based chemotherapy in survivors of cancer: a scoping review. Front Oncol. 2018;8:363. https://doi.org/10.3389/fonc.2018.00363.
Steyger PS. Mechanisms of ototoxicity and otoprotection. Otolaryngol Clin North Am. 2021;54(6):1101–15. https://doi.org/10.1016/j.otc.2021.08.007.
Dillard LK, Lopez-Perez L, Martinez RX, Fullerton AM, Chadha S, McMahon CM. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: a systematic review and meta-analysis. Cancer Epidemiol. 2022;79:102203. https://doi.org/10.1016/j.canep.2022.102203.
Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol. 2016;34(23):2712–20. https://doi.org/10.1200/JCO.2016.66.8822.
Sheth S, Mukherjea D, Rybak LP, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 2017;11:338. https://doi.org/10.3389/fncel.2017.00338.
Dille MF, McMillan GP, Reavis KM, Jacobs P, Fausti SA, Konrad-Martin D. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model. J Acoust Soc Am. 2010;128(3):1163. https://doi.org/10.1121/1.3473693.
Cancer Statistics - NCI. Published April 2, 2015. Accessed September 12, 2022. https://www.cancer.gov/about-cancer/understanding/statistics.
Pearson SE, Taylor J, Patel P, Baguley DM. Cancer survivors treated with platinum-based chemotherapy affected by ototoxicity and the impact on quality of life: a narrative synthesis systematic review. Int J Audiol. 2019;58(11):685–95. https://doi.org/10.1080/14992027.2019.1660918.
Bezjak A, Lee CW, Ding K, et al. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol. 2008;26(31):5052–9. https://doi.org/10.1200/JCO.2007.12.6094.
Ardeshirrouhanifard S, Fossa SD, Huddart R, et al. Ototoxicity after cisplatin-based chemotherapy: factors associated with discrepancies between patient-reported outcomes and audiometric assessments. Ear Hear. 2022;43(3):794–807. https://doi.org/10.1097/AUD.0000000000001172.
Falchook AD, Green R, Knowles ME, et al. Comparison of patient- and practitioner-reported toxic effects associated with chemoradiotherapy for head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2016;142(6):517–23. https://doi.org/10.1001/jamaoto.2016.0656.
Chou R, Dana T, Bougatsos C, Fleming C, Beil T. Screening adults aged 50 years or older for hearing loss: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2011;154(5):347–55. https://doi.org/10.7326/0003-4819-154-5-201103010-00009.
Lin FR, Yaffe K, Xia J, et al. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013;173(4):293. https://doi.org/10.1001/jamainternmed.2013.1868.
Cunningham LL, Tucci DL. Hearing loss in adults. N Engl J Med. 2017;377(25):2465–73. https://doi.org/10.1056/NEJMra1616601.
Graydon K, Waterworth C, Miller H, Gunasekera H. Global burden of hearing impairment and ear disease. J Laryngol Otol. 2019;133(1):18–25. https://doi.org/10.1017/S0022215118001275.
Thomson RS, Auduong P, Miller AT, Gurgel RK. Hearing loss as a risk factor for dementia: a systematic review. Laryngoscope Investig Otolaryngol. 2017;2(2):69–79. https://doi.org/10.1002/lio2.65.
Cudmore V, Henn P, O’Tuathaigh CMP, Smith S. Age-related hearing loss and communication breakdown in the clinical setting. JAMA Otolaryngol Head Neck Surg. 2017;143(10):1054–5. https://doi.org/10.1001/jamaoto.2017.1248.
Weinreich HM. Hearing loss and patient-physician communication: the role of an otolaryngologist. JAMA Otolaryngol Head Neck Surg. 2017;143(10):1055–7. https://doi.org/10.1001/jamaoto.2017.1242.
Kros CJ, Steyger PS. Aminoglycoside- and cisplatin-induced ototoxicity: mechanisms and otoprotective strategies. Cold Spring Harb Perspect Med. 2019;9(11):a033548. https://doi.org/10.1101/cshperspect.a033548.
Konrad-Martin D, Poling GL, Garinis AC, et al. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions. Int J Audiol. 2018;57(sup4):S3–18. https://doi.org/10.1080/14992027.2017.1398421.
American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. Available from www.asha.org/policy.
American Academy of Audiology. Position statement and clinical practice guidelines: ototoxicity monitoring. Published online 2009. https://www.audiology.org/wp-content/uploads/2021/05/OtoMonGuidelines.pdf_539974c40999c1.58842217.pdf. Accessed 4 Jan 2023.
American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS). Position statement: ototoxicity. Published 2015. https://www.entnet.org/resource/position-statement-ototoxicity/. Accessed 12 Sept 2022.
World Health Organization. World Report on Hearing. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/339913. Accessed 8 Sept 2021.
Professional Board for Speech, Language, and Hearing Professions. Audiological management of patients on treatment that includes ototoxic medications: guidelines. Published online 2018. https://www.hpcsa.co.za/Uploads/SLH/Guidelines%20for%20Audiological%20Management%20of%20Patients%20on%20Treatment%20that%20includes%20Ototoxic%20Medications.pdf.
Meijer AJM, van den Heuvel-Eibrink MM, Brooks B, et al. Recommendations for age-appropriate testing, timing, and frequency of audiologic monitoring during childhood cancer treatment: an International Society of Paediatric Oncology Supportive Care Consensus Report. JAMA Oncol. 2021;7(10):1550–8. https://doi.org/10.1001/jamaoncol.2021.2697.
Folmer RL, Saunders GH, Vachhani JJ, et al. Hearing health care utilization following automated hearing screening. J Am Acad Audiol. 2021;32(4):235–45. https://doi.org/10.1055/s-0041-1723041.
Konrad-Martin D, O’Connell Bennett K, Garinis A, McMillan GP. A Randomized controlled trial using automated technology for improving ototoxicity monitoring in VA oncology patients. Am J Audiol. 2021;30(3S):870–86. https://doi.org/10.1044/2021_AJA-21-00032.
Santucci NM, Garber B, Ivory R, Kuhn MA, Stephen M, Aizenberg D. Insight into the current practice of ototoxicity monitoring during cisplatin therapy. J Otolaryngol Head Neck Surg. 2021;50(1):19. https://doi.org/10.1186/s40463-021-00506-0.
Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. https://doi.org/10.1186/1748-5908-4-50.
Keith RE, Crosson JC, O’Malley AS, Cromp D, Taylor EF. Using the Consolidated Framework for Implementation Research (CFIR) to produce actionable findings: a rapid-cycle evaluation approach to improving implementation. Implement Sci. 2017;12(1):15. https://doi.org/10.1186/s13012-017-0550-7.
Means AR, Kemp CG, Gwayi-Chore MC, et al. Evaluating and optimizing the consolidated framework for implementation research (CFIR) for use in low- and middle-income countries: a systematic review. Implement Sci. 2020;15(1):17. https://doi.org/10.1186/s13012-020-0977-0.
Kilbourne AM, Goodrich DE, Miake-Lye I, Braganza MZ, Bowersox NW. Quality Enhancement research initiative implementation roadmap: toward sustainability of evidence-based practices in a learning health system. Med Care. 2019;57 Suppl 10 Suppl 3:S286-S293. https://doi.org/10.1097/MLR.0000000000001144.
Atkins D, Kilbourne AM, Shulkin D. Moving from discovery to system-wide change: the role of research in a learning health care system: experience from three decades of health systems research in the veterans health administration. Annu Rev Public Health. 2017;38:467–87. https://doi.org/10.1146/annurev-publhealth-031816-044255.
Department of Veterans Affairs (VA), Maintaining Internal Systems and Strengthening Integrated Outside Networks, (MISSION) Act Section 505(b). Annual Report. Published online 2020. Accessed September 9, 2022. https://www.va.gov/EMPLOYEE/docs/Section-505-Annual-Report-2020.pdf.
Veterans Benefits Administration. Annual benefits report fiscal year 2021. Published online 2021. Accessed July 29, 2022. https://www.benefits.va.gov/REPORTS/abr/docs/2021-abr.pdf.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. https://doi.org/10.1191/1478088706qp063oa.
Paken J, Govender CD, Pillay M, Sewram V. Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting. BMC Health Serv Res. 2022;22(1):791. https://doi.org/10.1186/s12913-022-08099-8.
Durlak JA, DuPre EP. Implementation matters: a review of research on the influence of implementation on program outcomes and the factors affecting implementation. Am J Community Psychol. 2008;41(3–4):327–50. https://doi.org/10.1007/s10464-008-9165-0.
Clark KD, Garinis AC, Konrad-Martin D. Incorporating patient narratives to enhance audiological care and clinical research outcomes. Am J Audiol. 2021;30(3S):916–21. https://doi.org/10.1044/2021_AJA-20-00228.
Yueh B, Collins MP, Souza PE, et al. Long-term effectiveness of screening for hearing loss: the screening for auditory impairment–which hearing assessment test (SAI-WHAT) randomized trial. J Am Geriatr Soc. 2010;58(3):427–34. https://doi.org/10.1111/j.1532-5415.2010.02738.x.
Donahue A, Dubno JR, Beck L. Guest editorial: accessible and affordable hearing health care for adults with mild to moderate hearing loss. Ear Hear. 2010;31(1):2–6. https://doi.org/10.1097/AUD.0b013e3181cbc783.